drugset / Trial / NCT06323928

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT06323928

Phase 2 Completed 874 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

Timeline

Start
2024-04-01
Primary completion
2026-01-16
Completion
2026-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AG09222 Monoclonal antibody Subcutaneous

Indications